Literature DB >> 14607712

Expressions of vascular endothelial growth factor in cirrhotic tissues and their relations to proto-oncogene c-fos, c-myc.

Bao-Min Shi1, Xiu-Yan Wang, Qing-Ling Mu, Tai-Huang Wu, Zhen Yang, Li Zhang, Da-Peng Li.   

Abstract

OBJECTIVE: To investigate the significance of vascular endothelial growth factor (VEGF) in the pathogenesis of liver cirrhosis and the correlation between VEGF and proto-oncogene c-fos and c-myc in cirrhotic liver.
METHODS: The proteins of VEGF, c-fos, and c-myc were identified immunohistochemically in each tissue section of 53 cases of liver cirrhosis. The correlations between VEGF, c-fos and c-myc were analyzed. The levels of VEGF protein in different Child gradings were also compared.
RESULTS: The proteins of VEGF were more highly expressed in Child A and B patients than in Child C patients and controls. The expressions of both c-fos and c-myc were not statistically significant between VEGF positive and negative patients.
CONCLUSIONS: The protein level of VEGF can reflect the compensation status of cirrhosis patients and may act as an anti-cirrhotic factor. The proto-oncogene c-fos, c-myc and VEGF may have different mechanisms in the course of cirrhosis or hepatic tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14607712

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  3 in total

1.  Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats.

Authors:  Yu Wang; Fan Lian; Jiaping Li; Wenzhe Fan; Hanshi Xu; Xiuyan Yang; Liuqin Liang; Wei Chen; Jianyong Yang
Journal:  J Transl Med       Date:  2012-06-26       Impact factor: 5.531

2.  Angiogenic factor expression in hepatic cirrhosis.

Authors:  Alexandra Giatromanolaki; Stamatia Kotsiou; Michael I Koukourakis; Efthimios Sivridis
Journal:  Mediators Inflamm       Date:  2007-02-28       Impact factor: 4.711

Review 3.  How VEGF-A and its splice variants affect breast cancer development - clinical implications.

Authors:  Hivin Al Kawas; Inas Saaid; Paul Jank; Christina C Westhoff; Carsten Denkert; Therese Pross; Karoline Barbara Stephanie Weiler; Maria Margarete Karsten
Journal:  Cell Oncol (Dordr)       Date:  2022-03-18       Impact factor: 7.051

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.